A Pilot Phase 1 Study of Intrathecal Pemetrexed for Refractory Leptomeningeal Metastases From Non-small-cell Lung Cancer

Zhenyu Pan, Guozi Yang, Jiuwei Cui, Wei Li, Yu Li, Pengxiang Gao, Tongchao Jiang, Yanan Sun, Lihua Dong, Yuanyuan Song, Gang Zhao, Zhenyu Pan, Guozi Yang, Jiuwei Cui, Wei Li, Yu Li, Pengxiang Gao, Tongchao Jiang, Yanan Sun, Lihua Dong, Yuanyuan Song, Gang Zhao

Abstract

Objectives: We aim to determine the feasibility, safety, maximally tolerated dose (MTD), recommended dose and potential anti-tumor activity of intrathecal pemetrexed (IP). Materials and Methods: Lung adenocarcinoma patients with recurrent or progressive leptomeningeal metastases (LM) after intrathecal chemotherapy were recruited. IP dose was escalated from 10 mg. A minimum of three patients and a maximum of six were enrolled in each cohort. Schedule protocol was IP twice per week for 2 weeks in induction therapy, followed by once per week for 4 weeks in consolidation therapy. Serial samples of plasma and cerebrospinal fluid (CSF) were obtained for pharmacokinetic studies. Results: Thirteen patients were enrolled between March 2017 and July 2018. EGFR driver oncogene was identified in most of the patients. Severe adverse events (AEs) were encountered in 31% (4/13) of the cases, including myelosuppression, radiculitis, and elevation of hepatic aminotransferases (EHA). Study protocol was revised due to lethal myelosuppression. Following protocol revision, vitamin B12 and folic acid supplementation was given at the beginning of treatment, and myelosuppression was well-controlled. Dose-limiting toxicities (DLT) were myelosuppression, radiculitis, and EHA. Two patients (2/2) developed dose-limiting myelosuppression at 15 mg level. One patient (1/6) experienced dose-limiting radiculitis and EHA at 10 mg level. MTD was 10 mg. Response rate was 31% (4/13) and disease control rate was 54% (7/13). The drug concentration showed a decreasing trend in serial CSF samples following each IP. After IP, the peak plasma concentration was reached at 4 h in two cases, 6 h in two cases, 9 h in one case, and 12 h in one case, respectively. Conclusion: Pemetrexed was appropriate for intrathecal administration. IP at 10 mg dose in combination with vitamin supplementation on the schedule of 1-2 times per week showed controllable toxicity and good efficacy. This regimen paves the way for subsequent clinical trial. Clinical Trial Registration: www.ClinicalTrials.gov, identifier NCT03101579.

Keywords: intrathecal chemotherapy; leptomeningeal metastases; non-small cell lung cancer; pemetrexed; refractory.

Figures

Figure 1
Figure 1
Study schema.
Figure 2
Figure 2
Study profile. IP, intrathecal pemetrexed; DLT, dose-limiting toxicity; AEs, adverse events; MTD, maximally tolerated dose.
Figure 3
Figure 3
(A) CSF pemetrexed concentration after each time of intrathecal pemetrexed. (B) Plasma pemetrexed concentration at different time points after intrathecal pemetrexed. No, patient number.

References

    1. Le Rhun E, Weller M, Brandsma D, Van den Bent M, de Azambuja E, Henriksson R, et al. . EANO-ESMO clinical practice guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. Ann Oncol. (2017) 28:iv84–99.10.1093/annonc/mdx221
    1. Groves MD, Glantz MJ, Chamberlain MC, Baumgartner KE, Conrad CA, Hsu S, et al. . A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro Oncol. (2008) 10:208–15.10.1215/15228517-2007-059
    1. Gammon DC, Bhatt MS, Tran L, Van Horn A, Benvenuti M, Glantz MJ. Intrathecal topotecan in adult patients with neoplastic meningitis. Am J Health Syst Pharm. (2006) 63:2083–6.10.2146/ajhp060165
    1. Chamberlain MC, Tsao-Wei DD, Groshen S. Phase II trial of intracerebrospinal fluid etoposide in the treatment of neoplastic meningitis. Cancer. (2006) 106:2021–7.10.1002/cncr.21828
    1. Blaney SM, Balis FM, Berg S, Arndt CA, Heideman R, Geyer JR, et al. . Intrathecal mafosfamide: a preclinical pharmacology and phase I trial. J Clin Oncol. (2005) 23:1555–63.10.1200/JCO.2005.06.053
    1. Bernardi RJ, Bomgaars L, Fox E, Balis FM, Egorin MJ, Lagattuta TF, et al. . Phase I clinical trial of intrathecal gemcitabine in patients with neoplastic meningitis. Cancer Chemother Pharmacol. (2008) 62:355–61.10.1007/s00280-007-0601-x
    1. Barlesi F, Gervais R, Lena H, Hureaux J, Berard H, Paillotin D, et al. . Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07–01). Ann Oncol. (2011) 22:2466–70.10.1093/annonc/mdr003
    1. Dai H, Chen Y, Elmquist WF. Distribution of the novel antifolate pemetrexed to the brain. J Pharmacol Exp Ther. (2005) 315:222–9.10.1124/jpet.105.090043
    1. Sorensen JB. Pharmacokinetic evaluation of pemetrexed. Expert Opin Drug Metab Toxicol. (2011) 7:919–28.10.1517/17425255.2011.587411
    1. Kumthekar P, Grimm SA, Avram MJ, Kaklamani V, Helenowski I, Rademaker A, et al. Pharmacokinetics and efficacy of pemetrexed in patients with brain or leptomeningeal metastases. J Neurooncol. (2013) 112:247–55.10.1007/s11060-013-1055-0
    1. Bearz A, Garassino I, Tiseo M, Caffo O, Soto-Parra H, Boccalon M, et al. . Activity of pemetrexed on brain metastases from non-small cell lung cancer. Lung Cancer. (2010) 68:264–8.10.1016/j.lungcan.2009.06.018
    1. Sun JM, Nam MH, Chung JY, Im B, Lee SY, Suh YL, et al. . Safety and pharmacokinetics of intrathecal administration of pemetrexed in rats. Cancer Chemother Pharmacol. (2011) 68:531–8.10.1007/s00280-010-1522-7
    1. Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Marini L, Del Tacca M, et al. . Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non-small-cell lung cancer cells. Mol Pharmacol. (2005) 68:110–8.10.1124/mol.104.009373
    1. Fleischhack G, Jaehde U, Bode U. Pharmacokinetics following intraventricular administration of chemotherapy in patients with neoplastic meningitis. Clin Pharmacokinet. (2005) 44:1–31.10.2165/00003088-200544010-00001
    1. Kutcher ME, Cripps MW, McCreery RC, Crane IM, Greenberg MD, Cachola LM, et al. . Criteria for empiric treatment of hyperfibrinolysis after trauma. J Trauma Acute Care Surg. (2012) 73:87–93.10.1097/TA.0b013e3182598c70
    1. Courchesne E, Chisum HJ, Townsend J, Cowles A, Covington J, Egaas B, et al. . Normal brain development and aging: quantitative analysis at in vivo MR imaging in healthy volunteers. Radiology. (2000) 216:672–82.10.1148/radiology.216.3.r00au37672
    1. Chan D, Chen V, Helfrich B, Zhang Z, Hirsch F, Ma D, et al. Preclinical studies of pemetrexed and gemcitabine, alone and in combinations, in human lung cancers. AACR Meeting Abstracts. (2006) 66:1278b Available online at:
    1. Latz JE, Chaudhary A, Ghosh A, Johnson RD. Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients. Cancer Chemother Pharmacol. (2006) 57:401–11.10.1007/s00280-005-0036-1
    1. Mita AC, Sweeney CJ, Baker SD, Goetz A, Hammond LA, Patnaik A, et al. . Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol. (2006) 24:552–62.10.1200/JCO.2004.00.9720
    1. Chamberlain M, Junck L, Brandsma D, Soffietti R, Ruda R, Raizer J, et al. . Leptomeningeal metastases: a RANO proposal for response criteria. Neuro Oncol. (2017) 19:484–92.10.1093/neuonc/now183
    1. Le Rhun E, Devos P, Boulanger T, Smits M, Brandsma D, Ruda R, et al. . The RANO leptomeningeal metastasis group proposal to assess response to treatment: lack of feasibility and clinical utility, and a revised proposal. Neuro Oncol. (2019) 21:648–58.10.1093/neuonc/noz024
    1. Zhang JP, Lee EQ, Nayak L, Doherty L, Kesari S, Muzikansky A, et al. . Retrospective study of pemetrexed as salvage therapy for central nervous system lymphoma. J Neurooncol. (2013) 115:71–7.10.1007/s11060-013-1196-1
    1. Sun Y, Wang Y, Han S, Xing B, Li H, Zhu Y, et al. . Efficacy and safety of pemetrexed on recurrent primary central nervous system lymphomas in China: a prospective study. Onco Targets Ther. (2017) 10:2595–600.10.2147/OTT.S134684
    1. Raizer JJ, Rademaker A, Evens AM, Rice L, Schwartz M, Chandler JP, et al. . Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphoma. Cancer. (2012) 118:3743–8.10.1002/cncr.26709
    1. Singh N, Aggarwal AN, Kaur J, Behera D. Association of graded folic acid supplementation and total plasma homocysteine levels with hematological toxicity during first-line treatment of nonsquamous NSCLC patients with pemetrexed-based chemotherapy. Am J Clin Oncol. (2017) 40:75–82.10.1097/COC.0000000000000111
    1. Adjei AA. Pharmacology and mechanism of action of pemetrexed. Clin Lung Cancer. (2004) 5(Suppl 2):S51–5.10.3816/CLC.2004.s.003
    1. Calvert AH, Walling JM. Clinical studies with MTA. Br J Cancer. (1998) 78(Suppl 3):35–40.10.1038/bjc.1998.752
    1. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. . Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. (2003) 21:2636–44.10.1200/JCO.2003.11.136
    1. Kim YS, Sun JM, Ahn JS, Ahn MJ, Park K. The optimal duration of vitamin supplementation prior to the first dose of pemetrexed in patients with non-small-cell lung cancer. Lung Cancer. (2013) 81:231–5.10.1016/j.lungcan.2013.04.011
    1. Ahn MJ, Kim DW, Cho BC, Kim SW, Lee JS, Ahn JS, et al. . Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study. Lancet Respir Med. (2017) 5:891–902.10.1016/S2213-2600(17)30378-8

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren